Oncoinvent (7BG) Stock Overview
A clinical stage company, develops radiopharmaceutical therapies against cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
7BG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Oncoinvent ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 7.96 |
| 52 Week High | NOK 9.04 |
| 52 Week Low | NOK 0.0001 |
| Beta | 0 |
| 1 Month Change | 84.26% |
| 3 Month Change | 84.26% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 52.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7BG | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 10.2% | -2.0% | 0.1% |
| 1Y | n/a | 36.5% | -0.5% |
Return vs Industry: Insufficient data to determine how 7BG performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 7BG performed against the German Market.
Price Volatility
| 7BG volatility | |
|---|---|
| 7BG Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 7BG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7BG's weekly volatility has decreased from 2676% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 44 | Oystein Soug | www.oncoinvent.com |
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.
Oncoinvent ASA Fundamentals Summary
| 7BG fundamental statistics | |
|---|---|
| Market cap | €34.87m |
| Earnings (TTM) | -€14.17m |
| Revenue (TTM) | €2.57m |
Is 7BG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7BG income statement (TTM) | |
|---|---|
| Revenue | NOK 28.07m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 28.07m |
| Other Expenses | NOK 183.14m |
| Earnings | -NOK 155.07m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 27, 2026
| Earnings per share (EPS) | -34.63 |
| Gross Margin | 100.00% |
| Net Profit Margin | -552.46% |
| Debt/Equity Ratio | 0% |
How did 7BG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 23:39 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncoinvent ASA is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geir Holom | DNB Carnegie |